Certain Common Stock of Evoke Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2024.
May 08, 2024
Share
Certain Common Stock of Evoke Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2024. These Common Stock will be under lockup for 91 days starting from 8-FEB-2024 to 9-MAY-2024.
Details:
The company's executive officers and directors have agreed with the Representative to be subject to a lock-up period of 90 days following the date of closing of the offering pursuant to this prospectus. This means that, during the lock-up period, such persons may not offer for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any shares of the company's common stock or any securities convertible into, or exercisable or exchangeable for, shares of Common Stock, subject to certain customary exceptions.
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
EVOKE PHARMA, INC. 
